Manufacturing Round-Up: Dr Reddy’s Receives Form 483 With Five Observations
As firms including Laurus Labs, Natco and Strides get GMP compliance nods, the FDA has pulled up Dr Reddy’s for GMP compliance issues. Meanwhile, Numaferm has struck a licensing deal and Olon has started constructing a new plant.
You may also be interested in...
Launching the oncology drug bortezomib in 14 European countries helped Stada to record an 11% increase in both Generics and group sales in the first half of 2019. But the German group, which is about to start rolling out biosimilar teriparatide, has suffered a legal setback on pemetrexed in its home market.
Even after the US FDA warns Strides on uncontrolled records destruction and poor OOS investigations at its Puducherry plant, firm remains confident in its US market growth projections.
Dr Reddy’s will be alone in the US market for six months with the first generic rival to Pfizer’s Hemabate carboprost brand.